Prosecutors in Manhattan on Thursday filed a revised indictment of Mathew Martoma, the former SAC Capital portfolio manager charged last November with illegal trading of two drug stocks in what was billed as the largest insider trading case in U.S. history.
This fresh Martoma indictment had been anticipated for several weeks and contains a number of intriguing new details, but it also underscores the government’s awkward position in the SAC case.
Martoma has pleaded not guilty. Prosecutors badly need him to flip to help them build a case against Cohen, which has long been their goal. So far, however, Martoma has refused—even in the face of seemingly insurmountable evidence, if the charges are to be believed.
This latest move suggests that prosecutors are going to keep coming down brutally hard on Martoma, a father of three, in the hopes that he changes his mind. His lawyer, Richard Strassberg at Goodwin Procter, didn’t respond to a request for comment.
The indictment introduces a new character to the drama, a co-conspirator referred to as Doctor-2. He served as a clinical investigator for the drug company Elan, helping to test an Alzheimer’s drug. Martoma arranged for paid consultations with Doctor-2 through a “financial services firm that provided expert networking services to the SAC Hedge Fund,” the government alleges, and Doctor-2 then leaked confidential drug trial data to the SAC trader.
To access the complete Businessweek article hit the link below